Today, the Government published the final report of its Accelerated Access Review (AAR), which made recommendations on speeding up patient access to new innovative medicines, medical technologies, as well as diagnostic and digital products available on the NHS.
Responding to this, Kevin Armstrong, Head of Policy and Campaigns at Pancreatic Cancer UK said:
“We hope the recommendations made in today’s AAR will help address unmet need within the NHS and ensure promising new innovations are made available more quickly to patients facing less survivable cancers, including pancreatic cancer.
“We are very glad to see the report calling on the National Institute of Health and Care Excellence (NICE) to review its health technology assessment processes and methods.
Through our own Key to Survival campaign, we are calling for a reformed system that has the flexibility needed to ensure that all cancer patients are able to access effective new treatments.
“There are very few treatments for pancreatic cancer, and just five per cent of patients currently live for five years after diagnosis, so we hope that these proposals will bring much needed improvement to treatment availability and survival rates respectively. We will be watching closely to ensure less survivable cancers such as pancreatic cancer aren’t left behind once the AAR’s recommendations are implemented.”